DDDD 4d Pharma Plc

TIDMDDDD

4d Pharma PLC

23 September 2019

Non-Regulatory

4D pharma plc

(the "Company" or "4D")

Publication of data on neurodegenerative disease programmes

4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper outlining the ability of MRx0005 and MRx0029 to modulate neuroinflammatory and neurodegenerative processes in vitro.

The paper 'In vitro characterisation of gut microbiota-derived bacterial strains with neuroprotective properties' (Ahmed et al.) is published in the journal Frontiers in Cellular Neuroscience.

Through screening a panel of gut bacterial strains using the Company's MicroRx(R) platform, 4D researchers have identified two single-strain Live Biotherapeutic candidates, MRx0005 (Parabacteroides distasonis) and MRx0029 (Megasphaera massiliensis), with potent effects on neuroinflammation and intrinsic antioxidant capacity. MRx0029 also displayed neuroprotective properties and induced a mature phenotype in undifferentiated neuronal cells. The team were able to associate many of the observed effects with specific short-chain fatty acids produced by the bacteria.

The Company has previously presented additional data demonstrating the efficacy of MRx0029 and MRx0005 in the MPTP model of Parkinson's disease.

Dr Alex Stevenson, 4D's Chief Scientific Officer, commented: "Neurodegenerative diseases, such as Parkinson's disease, are areas of high unmet need that have historically been challenging for the pharmaceutical industry. Single-strain Live Biotherapeutics present an opportunity as disease-modifying therapies to fundamentally change the way these patients are treated."

He added: "As we make good clinical progress with our lead programmes in cancer, asthma and gastrointestinal disease, our scientists continue to produce world-leading research to identify the next generation of Live Biotherapeutics."

Please find a copy of the paper here: https://www.frontiersin.org/articles/10.3389/fncel.2019.00402/full

 
For further information please contact: 
4D 
 Duncan Peyton, Chief Executive Officer      + 44 (0)113 895 0130 
 N+1 Singer - Nominated Adviser and Joint 
  Broker                                     +44 (0) 20 7496 3000 
 Aubrey Powell/ Justin McKeegan/ Alex Bond 
  (Corporate Finance) 
  Tom Salvesen (Corporate Broking) 
 Bryan Garnier & Co. Limited - Joint Broker  +44 (0)20 7332 2500 
 Dominic Wilson /Phil Walker 
 
  About 4D 
 
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, 
 a novel and emerging class of drugs, defined by the FDA as biological products that contain 
 a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure 
 of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies 
 Live Biotherapeutics based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic 
 products are orally delivered single strains of bacteria that are naturally found in the healthy 
 human gut. The Company has four clinical studies in progress, namely a Phase II clinical study 
 of Blautix in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with 
 KEYTRUDA(R) (pembrolizumab) in solid tumours, a Phase Ib study of MRx0518 in a neoadjuvant 
 setting for patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma. Other 
 focus programmes include disease areas such as CNS disease. 
 
 

For more information, refer to https://www.4dpharmaplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUUOWRKVAKUAR

(END) Dow Jones Newswires

September 23, 2019 02:01 ET (06:01 GMT)

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mag 2023 a Mag 2024